Maladaptive arterial remodeling with systemic hypertension associated with increased concentrations in blood of plasminogen activator inhibitor type-1 (PAI-1)

American Journal of Cardiology

Volumn 93, Issue 8, 2004, Pages 997-1001

  Furumoto, Tomoo ^b   Fujii, Satoshi ^b   Nishihara, Keiko ^b   Yamada, Satoshi ^b   Komuro, Kaoru ^b   Goto, Kazutomo ^b   Onozuka, Hisao ^b   Mikami, Taisei ^b   Kitabatake, Akira ^b   Sobel, Burton E ^a  

^a University of Vermont Colchester Research Facility   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; AGE DETERMINATION; AGED; ARTERY RECONSTRUCTION; ARTICLE; BRACHIAL ARTERY; CELL MIGRATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORRELATION ANALYSIS; ESSENTIAL HYPERTENSION; FEMALE; HEART VENTRICLE CONTRACTILITY; HEART VENTRICLE WALL; HUMAN; HYPERTENSION; INTIMA; MALE; MUSCLE CELL; PRIORITY JOURNAL; SEX DIFFERENCE; THICKNESS; TUNICA MEDIA; VASCULAR SMOOTH MUSCLE;

CAROTID ARTERIES; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; MUSCLE, SMOOTH, VASCULAR; PLASMINOGEN ACTIVATOR INHIBITOR 1; TUNICA INTIMA; TUNICA MEDIA;

EID: 11144358152     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2003.12.053     Document Type: Article

References (19)

1. Furumoto T., Saito N., Dong J., Mikami T., Fujii S., Kitabatake A. Association of cardiovascular risk factors and endothelial dysfunction in Japanese hypertensive patients implications for early atherosclerosis. Hypertens Res. 25:2002;475-480.
2. Sobel B.E. Increased plasminogen activator inhibitor-1 and vasculopathy. A reconcilable paradox. Circulation. 99:1999;2496-2498.
3. Sobel B.E. The potential influence of insulin and plasminogen activator inhibitor type-1 on formulation of vulnerable atherosclerotic plaques associated with type 2 diabetes. Proc Assoc Am Physicians. 111:1999;313-318.
4. Sobel B.E., Woodcock-Mitchell J., Schneider D.J., Holt R.E., Marutsuka K., Gold H. Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients a potential factor predisposing to thrombosis and its persistence. Circulation. 97:1998;2213-2221.
5. Pandolfi A., Cetrullo D., Polishuck R., Alberta M.M., Calafiore A., Pellegrini G., Vitacolonna E., Capani F., Consoli A. Plasminogen activator inhibitor type 1 is increased in the arterial wall of type II diabetic subjects. Arterioscler Thromb Vasc Biol. 21:2001;1378-1382.
6. Shindo J., Ishibashi T., Kijima M., Nakazato K., Nagata K., Yokoyama K., Hirosaka A., Sato E., Hunii H., Yamaguchi N., et al. Increased plasminogen activator inhibitor-1 and apolipoprotein (a) in coronary atherectomy specimens in acute coronary syndromes. Coron Artery Dis. 12:2001;573-579.
7. Yamada S., Mikami T., Nishihara K., Mitake T., Izumi M., Yoshida N., Hanaoka A., Wu D., Komuro K., Onozuka H., Fujii S., Kitabatake A. Measuring medium-sized muscular arteries using a novel broadband 15-MHz linear array probe. J Med Ultrason. 30:2003;177-185.
8. Corretti M.C., Anderson T.J., Benjamin E.J., Celermajer D., Charbonneau F., Creager M.A., Deanfield J., Drexler H., Gerhard-Herman M., Herrington D., et al. International Brachial Artery Reactivity Task Force. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol. 39:2002;257-265.
9. Onozuka H., Fujii S., Mikami T., Yamada S., Ishimori N., Shimizu T., Komuro K., Nishihara K., Okamoto H., Kitabatake A. In vivo echocardiographic detection of cardiovascular lesions in apolipoprotein E-knockout mice using a novel high-frequency high-speed echocardiography. Circ J. 66:2002;272-276.
10. Girerd X., Mourad J.J., Copie X., Moulin C., Acar C., Safar M., Laurent S. Noninvasive detection of an increased vascular mass in untreated hypertensive patients. Am J Hypertens. 7:1994;1076-1083.
11. Sahn D.J., DeMaria A., Kisslo J., Weyman A. Recommendations regarding quantitation in M-mode echocardiography results of a survey of echocardiographic measurements. Circulation. 58:1978;1072-1083.
12. Devereux R.B., Reichek N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the methods. Circulation. 55:1977;613-618.
13. Kruszynska Y.T., Yu J.G., Olefsky J.M., Sobel B.E. Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects. Diabetes. 49:2000;633-639.
14. Toikka J.O., Laine H., Ahotupa M., Haapanen A., Viikari J.S., Hartiala J.J., Raitakari O.T. Increased arterial intima-media thickness and in vivo LDL oxidation in young men with borderline hypertension. Hypertension. 36:2000;929-933.
15. Singh T.P., Groehn H., Kazmers A. Vascular function and carotid intimal-medial thickness in children with insulin-dependent diabetes mellitus. J Am Coll Cardiol. 41:2003;661-665.
16. Sobel B.E., Taatjes D.J., Schneider D.J. Intramural plasminogen activator inhibitor type-1 (PAI-1) and coronary atherosclerosis. Arterioscler Thromb Vasc Biol. 23:2003;1979-1989.
17. Carmeliet P., Moons L., Lijnen R., Janssens S., Lupu F., Colen D., Gerard R.D. Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation a gene targeting and gene transfer study in mice. Circulation. 96:1997;3180-3191.
18. De Waard V., Arkenbout E.K., Carmeliet P., Lindner V., Pannekoek H. Plasminogen activator inhibitor 1 and vitronectin protect against stenosis in a murine carotid artery ligation model. Arterioslcer Thromb Vasc Biol. 22:2002;1978-1983.
19. Cai H., Li Z., Goette A., Mera F., Honeycutt C., Feterik K., Wilcox J.N., Dudley S.C. Jr, Harrison D.G., Langberg J.J. Downregulation of endocardial nitric oxide synthase expression and nitric oxide production in atrial fibrillation potential mechanisms for atrial thrombosis and stroke. Circulation. 106:2002;2854-2858.